Literature DB >> 35426131

Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.

Massimo Franchini1, Daniele Focosi2, Carlo Mengoli1, Elena Percivalle3,4, Josè Camilla Sammartino3,4, Alessandro Ferrari3,4, Matteo Zani1, Claudia Glingani1, Fausto Baldanti3,4.   

Abstract

BACKGROUND: Novel SARS-CoV-2 variants of concern (VOC) Delta and Omicron are able to escape some monoclonal antibody therapies, making again COVID-19 convalescent plasma (CCP) a potential frontline treatment. STUDY DESIGN/
METHODS: In this study, we investigated the kinetics of anti-SARS-CoV-2 neutralizing antibodies (nAbs) against VOCs Delta and Omicron in vaccine breakthrough infected plasma donors. Serum samples from 19 donors were collected at the time of plasma donation and tested for anti-SARS-CoV-2 nAbs (using live authentic VOC viral neutralization test) and IgG (Liaison® SARS-CoV-2 S1/S2 and Liaison® SARS-CoV-2 TrimericS IgG assays, DiaSorin). Measures were correlated with different variables, including the time between last vaccine dose and CCP donation, and time between SARS-COV-2 infection and CCP donation.
RESULTS: nAb titers against VOC Delta and Omicron were directly related to the time interval since last vaccine dose to CCP donation, but inversely related to time since COVID19 breakthrough infection. DISCUSSION: SARS-CoV-2 breakthrough infection in vaccinated in donors boosts nAb titers against VOCs Delta and Omicron, but such titers decay shortly after infection. Therefore, CCP must be collected early after vaccine breakthrough infection.
© 2022 AABB.

Entities:  

Keywords:  Donors

Mesh:

Substances:

Year:  2022        PMID: 35426131     DOI: 10.1111/trf.16887

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.337


  2 in total

1.  Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources.

Authors:  Daniele Focosi; Massimo Franchini; Michael J Joyner; Arturo Casadevall; David J Sullivan
Journal:  medRxiv       Date:  2022-08-05

2.  Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.

Authors:  Massimo Franchini; Daniele Focosi; Elena Percivalle; Massimiliano Beccaria; Martina Garuti; Omar Arar; Antonietta Pecoriello; Fabio Spreafico; Graziana Greco; Stefano Bertacco; Marco Ghirardini; Tiziana Santini; Michele Schiavulli; Muzzica Stefania; Thaililja Gagliardo; Josè Camilla Sammartino; Alessandro Ferrari; Matteo Zani; Alessia Ballotari; Claudia Glingani; Fausto Baldanti
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.